Pharmachim S.A. announces an exclusive commercialization agreement with Purpose Pharma for diflunisal in Greece and Cyprus
Athens, June 1st, 2026 – Pharmachim S.A., today announced a strategic, exclusive agreement with Purpose Pharma International AB, a European rare disease biophar...
Read more